Recent Updates
Recently added Catalysts
ARDX Positive Sentiment Score: 70/100

Ardelyx to Participate at the Jefferies London Healthcare Conference

Friday, November 10, 2023 2 min read
Key Takeaway: Ardelyx, Inc. will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2023. The event will be accessible online, with a replay available for 30 days. Ardelyx is dedicated to developing first-in-class medicines and currently has two commercial products, IBSRELA and XPHOZAH, approved in the U.S. The company is also expanding its reach with international partnerships for its product tenapanor.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ardelyx will present at the significant Jefferies London Healthcare Conference.
  • The company's mission focuses on addressing unmet medical needs with innovative medicines.
  • Ardelyx has approved products in the U.S. and ongoing international collaborations.

Full Press Release Details

WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Ardelyx management will participate in a fireside chat at the Jefferies London Healthcare Conference on Thursday, November 16, 2023, at 8:30 a.m. GMT in London, UK.
To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx website for 30 days following the event.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin has received approval for PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:

Frequently Asked Questions

What is Ardelyx, Inc. known for?

Ardelyx, Inc. specializes in discovering and commercializing innovative medicines.

When is Ardelyx presenting at the Jefferies Conference?

Ardelyx will present on November 16, 2023, at 8:30 a.m. GMT.

How can I access the Ardelyx presentation webcast?

The webcast is available on the Events & Presentations page of Ardelyx's website.

What products does Ardelyx have in the U.S.?

Ardelyx's approved products in the U.S. are IBSRELA® and XPHOZAH®.

Who commercializes IBSRELA in Canada?

IBSRELA is commercialized in Canada by Knight Therapeutics.

Tags: ARDX Viatris Investor Conferences Healthcare Ardelyx tenapanor IBSRELA XPHOZAH healthcare conference
Last updated: Nov 10, 2023